

## DAFTAR PUSTAKA

- Berrih-Aknin S. Role of the thymus in autoimmune myasthenia gravis. *Clinical and Experimental Neuroimmunology*. 2016;7(3):226-237.
- Boldingh M, Maniaol A, Brunborg C, Dekker L, Heldal A, Lipka A *et al*. Geographical Distribution of Myasthenia Gravis in Northern Europe - Results from a Population-Based Study from Two Countries. *Neuroepidemiology*. 2015;44(4):221-231.
- Breiner A, Widdifield J, Katzberg H, Barnett C, Bril V, Tu K. Epidemiology of myasthenia gravis in Ontario, Canada. *Neuromuscular Disorders*. 2016;26(1):41-46.
- Carr A, Cardwell C, McCarron P, McConville J. A systematic review of population based epidemiological studies in Myasthenia Gravis. *BMC Neurology*. 2010;10(1).
- Costanzo L. *Physiology*. 5th ed. Saunders Elsevier; 2014.
- Evoli A. Myasthenia gravis. *Current Opinion in Neurology*. 2017;30(5):464-470.
- Fang F, Sveinsson O, Thormar G, Granqvist M, Askling J, Lundberg I *et al*. The autoimmune spectrum of myasthenia gravis: a Swedish population-based study. 2020.
- Gattellari M, Goumas C, Worthington J. A national epidemiological study of Myasthenia Gravis in Australia. *European Journal of Neurology*. 2012;19(11):1413-1420.
- Hansen J, Danielsen D, Somnier F, Frøslev T, Jakobsen J, Johnsen S *et al*. Mortality in myasthenia gravis: A nationwide population-based follow-up study in Denmark. *Muscle & Nerve*. 2015;53(1):73-77.
- Hendricks T, Bhatti M, Hodge D, Chen J. Incidence, Epidemiology, and Transformation of Ocular Myasthenia Gravis: A Population-Based Study. *American Journal of Ophthalmology*. 2019;205:99-105.
- Hubbard S, Gnanasambandan K. Structure and activation of MuSK, a receptor tyrosine kinase central to neuromuscular junction formation. *Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics*. 2013;1834(10):2166-2169.
- Jayam Truth A, Dabi A, Solieman N, Kurukumbi M, Kalyanam J. Myasthenia Gravis: A Review. *Autoimmune Diseases*. 2012;2012:1-10.
- Lee H, Lee H, Shin H, Choi Y, Kim S. The Epidemiology of Myasthenia Gravis in Korea. *Yonsei Medical Journal*. 2016;57(2):419.

- Lefter S, Hardiman O, Ryan A. A population-based epidemiologic study of adult neuromuscular disease in the Republic of Ireland. *Neurology*. 2016;88(3):304-313.
- Liu F, Kuo C, See L, Tsai H, Yu H. Familial aggregation of myasthenia gravis in affected families: a population-based study. *Clinical Epidemiology*. 2017;Volume 9:527-535.
- Pallaver F, Riviera A, Piffer S, Ricciardi R, Roni R, Orrico D *et al*. Change in Myasthenia Gravis Epidemiology in Trento, Italy, after Twenty Years. *Neuroepidemiology*. 2011;36(4):282-287.
- Pekmezovic, Tatjana & Lavrnić, Dragana & Jarebinski, Mirjana & Apostolski, Slobodan. (2006). Epidemiology of Myasthenia gravis. *Srpski arhiv za celokupno lekarstvo*. 134. 453-6.
- Plomp J, Huijbers M, van der Maarel S, Verschuuren J. Pathogenic IgG4 subclass autoantibodies in MuSK myasthenia gravis. *Annals of the New York Academy of Sciences*. 2012;1275(1):114-122.
- Romi F, Hong Y, Gilhus N. Pathophysiology and immunological profile of myasthenia gravis and its subgroups. *Current Opinion in Immunology*. 2017;49:9-13.
- Ruff R, Lennon V. How myasthenia gravis alters the safety factor for neuromuscular transmission. *Journal of Neuroimmunology*. 2008;201-202:13-20.
- Woung L, Lin C, Chen T, Jou J. Update on ocular myasthenia gravis in Taiwan. *Taiwan Journal of Ophthalmology*. 2018;8(2):67.
- Zieda A, Ravina K, Glazere I, Pelcere L, Naudina M, Liepina L *et al*. A nationwide epidemiological study of myasthenia gravis in Latvia. 2017.